HTG Molecular Diagnostics and Firalis Announce an Agreement Enabling Firalis’ Commercialization of Theranostic and Research Products and Services Based on HTG EdgeSeq Technology

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) (“HTG”), a provider of instruments, reagents and services for molecular profiling applications, and Firalis S.A. (“Firalis”), a provider of bioanalytical services and biomarker-based products and services, today announced a non‑exclusive license and supply agreement (“Agreement”) that will enable Firalis to commercialize a next‑generation sequencing (NGS)‑based theranostic product and services to predict rheumatoid arthritis (RA) patients response to anti‑TNFα therapy, and other research products and services for mRNA profiling of inflammatory‑autoimmune disorders. The Agreement is a next step in the parties’ relationship following the successful adaptation of Firalis’ BIOPRED* research‑use assay to HTG EdgeSeq technology.https://finance.yahoo.com/news/htg-molecul...

Read more

Recommended & Related Posts

HTG Launches HTG EdgeSeq Reveal

$HTGM TUCSON, Ariz., Jan. 16, 2019 -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the.https://finance.yahoo.com/news/htg-launche...

Read more
HTG Molecular Announces Executive Transition Plan

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced a leadership transition plan in which TJ Johnson, Chief Executive Officer of HTG will assume the role of Executive Chairman of the Board of Directors of HTG.  John Lubniewski, President and Chief Operating Officer will succeed Mr. Johnson as Chief Executive Officer, and Dr. Ann Hanham, Ph.D. will assume the role of Lead Independent Director at the end of the first quarter 2019. “TJ has been a tremendous leader and a passionate advocate during his 11 years as CEO of the company.  His strategic vision and steadfast guidance have put HTG on a path of growth for years to come,” said Ann Hanham, Ph.D., Chair of HTG’s Board of Directors.https://finance.yahoo.com/news/htg-molecul...

Read more
HTG Announces Preliminary Full Year 2018 Unaudited Revenue of Approximately $21.5 Million

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced preliminary, unaudited financial results for the full year ended December 31, 2018. Total revenue for the full year 2018 is expected to be approximately $21.5 million, an increase of 46% over total revenue for the full year 2017. Product revenue for 2018 is expected to increase 25% over full year 2017.https://finance.yahoo.com/news/htg-announc...

Read more
HTG Establishes a French Subsidiary to Support Expanding Growth 

$HTGM HTG Molecular Diagnostics, Inc. (HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced the formation of a French subsidiary, HTG Molecular Diagnostics France SARL (“HTG France”) in November 2018. In conjunction with the subsidiary formation, HTG has also created an application incubator laboratory in Sausheim, France, which is expected to accelerate additional product applications and to provide direct customer service to European accounts.https://finance.yahoo.com/news/htg-establi...

Read more
TATAA Biocenter Expands Its Next-Generation Sequencing Offerings with HTG Molecular Diagnostics' Unique HTG EdgeSeq System

$HTGM GÖTEBORG, Sweden and TUSCON, Ariz., Dec. 05, 2018 (GLOBE NEWSWIRE) -- TATAA Biocenter, Europe's leading provider of genomic services, and HTG Molecular Diagnostics, Inc (HTG) (HTGM), a provider of instruments, reagents, and services for molecular profiling applications, today announced the expansion of TATAA Biocenter’s next-generation sequencing (NGS) offerings with HTG’s unique HTG EdgeSeq system. “The HTG EdgeSeq system is a conceptual breakthrough in targeted RNA sequencing offering superior sensitivity and specificity to traditional RNASeq approaches,” said Dr. Mikael Kubista, founder and CEO of TATAA Biocenter.https://finance.yahoo.com/news/tataa-bioce...

Read more

There are more for you ...

View more and participate in our discussion now. It's FREE.

Creating an account means you’re okay with InvestingNote's Terms and Conditions